Literature DB >> 22132966

ABCG2/BCRP dysfunction as a major cause of gout.

Hirotaka Matsuo1, Tappei Takada, Kimiyoshi Ichida, Takahiro Nakamura, Akiyoshi Nakayama, Hiroshi Suzuki, Tatsuo Hosoya, Nariyoshi Shinomiya.   

Abstract

Recent genome-wide association studies showed that serum uric acid (SUA) levels relate to ABCG2/BCRP gene, which locates in a gout-susceptibility locus revealed by a genome-wide linkage study. Together with the ABCG2 characteristics, we hypothesized that ABCG2 transports urate and its dysfunction causes hyperuricemia and gout. Transport assays showed ATP-dependent transport of urate via ABCG2. Kinetic analysis revealed that ABCG2 mediates high-capacity transport of urate (Km: 8.24 ± 1.44 mM) even under high-urate conditions. Mutation analysis of ABCG2 in 90 Japanese hyperuricemia patients detected six nonsynonymous mutations, including five dysfunctional variants. Two relatively frequent dysfunctional variants, Q126X and Q141K, were then examined. Quantitative trait locus analysis of 739 Japanese individuals showed that Q141K increased SUA as the number of minor alleles of Q141K increased (p = 6.60 × 10(-5)). Haplotype frequency analysis revealed that there is no simultaneous presence of Q126X and Q141K in one haplotype. Becuase Q126X and Q141K are assigned to nonfunctional and half-functional haplotypes, respectively, their genotype combinations are divided into four functional groups. The association study with 161 male gout patients and 865 male controls showed that all of those with dysfunctional ABCG2 increased the gout risk, especially those with ≤1/4 function (OR, 25.8; 95% CI, 10.3-64.6; p = 3.39 × 10(-21)). These genotypes were found in 10.1% of gout patients, but in only 0.9% of control. Our function-based clinicogenetic (FBCG) analysis showed that combinations of the two dysfunctional variants are major causes of gout, thereby providing a new approach for prevention and treatment of the gout high-risk population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22132966     DOI: 10.1080/15257770.2011.633954

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  11 in total

1.  Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.

Authors:  Kenneth K W To; Brian Tomlinson
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 2.  Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species.

Authors:  Ludwik Gorczyca; Lauren M Aleksunes
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-14       Impact factor: 4.481

Review 3.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 4.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 5.  Gout: a review of nonmodifiable and modifiable risk factors.

Authors:  Lindsey A MacFarlane; Seoyoung C Kim
Journal:  Rheum Dis Clin North Am       Date:  2014-09-02       Impact factor: 2.670

Review 6.  PharmGKB summary: very important pharmacogene information for ABCG2.

Authors:  Alison E Fohner; Deanna J Brackman; Kathleen M Giacomini; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2017-11       Impact factor: 2.089

7.  Serum Uric Acid Levels were Dynamically Coupled with Hemoglobin A1c in the Development of Type 2 Diabetes.

Authors:  Fengjiang Wei; Baocheng Chang; Xilin Yang; Yaogang Wang; Liming Chen; Wei-Dong Li
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379

Review 8.  Physiology, Development, and Disease Modeling in the Drosophila Excretory System.

Authors:  Erez Cohen; Jessica K Sawyer; Nora G Peterson; Julian A T Dow; Donald T Fox
Journal:  Genetics       Date:  2020-02       Impact factor: 4.562

9.  Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.

Authors:  Floriane Montanari; Anna Cseke; Katrin Wlcek; Gerhard F Ecker
Journal:  SLAS Discov       Date:  2016-07-11       Impact factor: 3.341

Review 10.  Prediction of drug-ABC-transporter interaction--Recent advances and future challenges.

Authors:  Floriane Montanari; Gerhard F Ecker
Journal:  Adv Drug Deliv Rev       Date:  2015-03-11       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.